Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors

Published:2012-07 Issue:7 Volume:23 Page:1659-1665
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Blay J.-Y.,Pérol D.,Le Cesne A.

Funder

Novartis Pharmaceuticals

NetSarc (Network for the Clinical Management of Sarcomas), RREPS (Réseau de Relecture en Pathologie des Sarcomes) and LYRIC

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/7/1659/522930/mdr622.pdf

Reference35 articles.

1. Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors;Blay;Cancer,2010

2. Molecular pathobiology of gastrointestinal stromal sarcomas;Corless;Annu Rev Pathol,2008

3. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors;Demetri;N Engl J Med,2002

4. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033;Blanke;J Clin Oncol,2008

5. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT;Blanke;J Clin Oncol,2008

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial;The Lancet Oncology;2024-09

2. A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.;Annals of Oncology;2024-09

3. Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?;Journal of Surgical Oncology;2024-06-24

4. Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study;Acta Oncologica;2024-05-07

5. FBXW7 regulates the sensitivity of imatinib in gastrointestinal stromal tumors by targeting MCL1;Gastric Cancer;2023-12-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3